Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus

Clinical Drug Investigation

Volumn 25, Issue 9, 2005, Pages 579-587

  Neuser, Dieter ^a   Benson, Alice ^b   Brückner, Andreas ^a   Goldberg, Ronald B ^c   Hoogwerf, Byron J ^d   Petzinna, Dieter ^a  

^a BAYER PHARMA AG   (Germany)

^b BAYER CORPORATION   (United States)

^c Lipid Disorder Center   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALANINE AMINOTRANSFERASE; ANTIANEMIC AGENT; ANTIULCER AGENT; ASPARTATE AMINOTRANSFERASE; CALCIUM; CYANOCOBALAMIN; FOLIC ACID; HEMOGLOBIN; INSULIN; PLACEBO; PYRIDOXINE; SULFONYLUREA; VITAMIN D;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CALCIUM BLOOD LEVEL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; FLATULENCE; FOLIC ACID BLOOD LEVEL; FREQUENCY ANALYSIS; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IRON BINDING CAPACITY; IRON BLOOD LEVEL; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN DISEASE; TITRIMETRY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; URINALYSIS; VALIDATION PROCESS; VITAMIN BLOOD LEVEL;

EID: 25644461255     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200525090-00003     Document Type: Article

References (22)

1. Laube H. Acarbose: an update of its therapeutic use in diabetes treatment. Clin Drug Invest 2002; 22 (3): 141-56
2. Dimitriadis G, Karaiskos C, Raptis S. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus. Horm Metab Res 1986; 18 (4): 253-5
3. Breuer H-WM. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther 2003; 41 (10): 421-40
4. Rios MS. Acarbose and insulin therapy in type 1 diabetes mellitus. Eur J Clin Invest 1994; 24 Suppl. 3: 36-9
5. Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type 1 diabetes. Diabetes Care 1997; 20 (3): 248-53
6. Sels JPJE, Verdonk HER, Wolffenbuttel BHR. Effects of acarbose (Glucobay®) in persons with type 1 diabetes: a multicentre study. Diabetes Res Clin Pract 1998; 41: 139-45
7. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002 Jun; 359: 2072-7
8. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 Jul; 290: 486-94
9. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-6
10. Hasche H, Mertes G, Bruns C, et al. Effects of acarbose treatment in type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab 1999; 12: 277-85
11. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193-204
12. Hollander P. Safety profile of acarbose, an α-glucosidase inhibitor. Drugs 1992; 47 Suppl. 2: 47-53
13. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57
14. May C. Efficacy and tolerability of stepwise increasing dosage of acarbose in patients with non-insulin-dependent diabetes mellitus (NIDDM), treated with sulfonylureas [in German]. Diabetes und Stoffwechsel 1995; 4: 3-8
15. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000; 16: 125-32
16. Duckworth WC. Hyperglycemia and cardiovascular disease. Curr Atheroscler Rep 2001; 3: 383-91
17. American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus. Endocr Pract 2002; 8 Suppl. 1: 40-82
18. Coniff R, Krol A. Acarbose: a review of US clinical experience. Clin Ther 1997; 19 (1): 16-26
19. Fischer S, Hanefeld M, Spengler M, et al. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol 1998; 35: 34-40
20. Coniff RF, Shapiro JA, Robbins D, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 1995; 18 (6): 817-24
21. Chiasson J-L, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121 (12): 928-35
22. Riccardi G, Giacco R, Parillo M, et al. Efficacy and safety of acarbose in the treatment of type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet Med 1999; 16: 228-32